Side-by-side · Research reference

SelankvsSurvodutide

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AHuman-MechanisticAUTO-DRAFTED11/40 cited

BPhase 3HUMAN-REVIEWED25/54 cited

Selank

Anxiolytic + Cognitive · Russian Pharma

150–300 mcg/doseIntranasalZaderej 2014

HumanMechanisticZaderej 2014 Medvedev 2007

~30 minOnset

Intranasal · 2–3×/day during stress / cognitive demand

Survodutide

GLP-1/Glucagon Dual Agonist · Phase 3

Once weeklyFrequency

Phase 3Development stageRubino 2026

GLP-1/GCGRDual targetZimmermann 2026

SQ · Once Weekly

01Mechanism of Action

Parameter

Selank

Survodutide

Primary target

Monoamine system (serotonin / GABA modulation) + immunomodulation via tuftsin domainZaderej 2014

GLP-1 receptor and glucagon receptor (GCGR)Yathindra 2026 Zimmermann 2026

Pathway

Tuftsin-derived immune signaling + CNS monoamine modulation → reduced anxiety + improved mood / cognitionMedvedev 2007

Central: CVOs → hypothalamic appetite regulation. Peripheral: GLP-1R → incretin effect; GCGR → hepatic lipid metabolism, energy expenditureZimmermann 2026 Long 2026

Downstream effect

Anxiolytic + cognitive enhancement; immunomodulation via increased IL-6 + IFN-γMedvedev 2007 Zaderej 2014

Decreased energy intake, increased energy expenditure, improved glucose homeostasis, hepatic fat reductionZimmermann 2026 Yathindra 2026

Feedback intact?

No GABA-receptor binding; no dependence reportedMedvedev 2007

—

Origin

Synthetic 7-AA peptide derived from human tuftsin (immune-system tetrapeptide)Zaderej 2014

—

Antibody development

—

02Dosage Protocols

Parameter

Selank

Survodutide

Standard dose

150–300 mcg / dose intranasalZaderej 2014

Not yet disclosed (Phase 3 ongoing)

SYNCHRONIZE Phase 3 program underway.Rubino 2026

Frequency

2–3× per day during stress

Once weekly

Lower / starter dose

75 mcg / dose

—

Evidence basis

Human-mechanistic + Russian clinical trialsMedvedev 2007

Phase 2 RCT (obesity) · Phase 3 ongoing

Duration

10–14 day cycles, repeated as needed

—

Reconstitution

Pre-formulated nasal spray (commercial); research vial: bacteriostatic water

—

Timing

Morning + early afternoon preferred

—

Half-life

Short (minutes plasma); CNS effect lasts ~3 hr

—

Route

—

SubcutaneousYathindra 2026

Phase 2 findings

—

Significant weight loss and metabolic marker improvementYathindra 2026

MASH indication

—

Under investigation for MASH-cirrhosisPatil 2026 Andonie 2026

03Metabolic / Fat Loss Evidence

Parameter

Selank

Survodutide

Primary fat target

—

Total body weight, visceral adipose tissue

Weight loss mechanism

—

Dual action: decreased energy intake + increased energy expenditureZimmermann 2026

Phase 2 efficacy

—

Significant weight loss demonstrated

Specific percentage not disclosed in abstracts.

Metabolic markers

—

Improvements in ALT, AST, LDL levels; significant ALT reduction (MD -22.10 vs placebo)Yathindra 2026 Abulehia 2026 Andonie 2026

MRI-PDFF reduction

—

Hepatic fat reduction demonstrated in MASH trialsAndonie 2026

Network meta-analysis

—

Favorable efficacy profile vs other glucagon receptor agonists

Hepatic requirement

—

Hepatic GCGR required for maximal weight loss and metabolic effectsLong 2026

Energy expenditure

—

Increased energy expenditure contributes to weight lossZimmermann 2026

Comparative efficacy

—

Network meta-analysis shows competitive efficacy in GRA class

04Side Effects & Safety

Parameter

Selank

Survodutide

Nasal irritation

Mild burning or congestion (transient)

—

Sedation

None — distinct from benzodiazepinesMedvedev 2007

—

Dependence / withdrawal

None reported in clinical useZaderej 2014

—

Cognitive impairment

None — opposite effect (enhancement)

—

Allergic reaction

Rare hypersensitivity

—

Long-term safety

Limited Western RCT data

—

Pregnancy / OB

Avoid — insufficient data

—

GI symptoms

—

Diarrhea, nausea, fatigue — class effect of GLP-1 agonists

Safety profile

—

Network meta-analysis: comparable safety to other GRAs

Serious adverse events

—

Monitored in Phase 2/3; no unique safety signals reported

Detailed SAE data pending Phase 3 completion.

Injection site reactions

—

Expected with subcutaneous administration

Glucagon-related effects

—

Potential for tachycardia, increased blood pressure — theoretical glucagon effect

Absolute Contraindications

Selank

·Pregnancy / breastfeeding
·Hypersensitivity to peptide

Survodutide

·Personal or family history of medullary thyroid carcinoma (class effect)
·Multiple endocrine neoplasia syndrome type 2

Relative Contraindications

Selank

·Active autoimmune disease (theoretical via immunomodulation)

Survodutide

·Severe GI disease (inflammatory bowel disease, gastroparesis)
·History of pancreatitis
·Cardiovascular disease (monitor closely for glucagon effects)

05Administration Protocol

Parameter

Selank

Survodutide

1. Form

Pre-formulated nasal spray (commercial) or research vial reconstituted with bacteriostatic water.

Specific reconstitution protocol not yet publicly disclosed. Follow manufacturer instructions upon approval.

2. Administration

Intranasal — 1–3 sprays per nostril per dose. Tilt head slightly back.

Subcutaneous — abdomen, thigh, or upper arm. Rotate sites weekly to minimize injection site reactions.

3. Timing

Morning + early afternoon for cognitive demand; PRN for acute anxiety.

Once weekly, same day each week. Can be administered at any time of day, with or without meals.

4. Storage

Refrigerate after reconstitution; ≤30 days. Light-protected.

Store refrigerated (2–8 °C) until use. Do not freeze. Protect from light. Specific reconstituted storage duration pending labeling.

5. Caveat

Avoid co-administration with strong sedatives or other anxiolytics initially.

Subcutaneous injection with appropriate gauge needle (typically 27–31G). Use sterile technique.